PetMed Express, Inc. Form 10-Q Summary
Reporting period: Quarter and six months ended September 30, 2023; fiscal year ends March 31. Financial statements are unaudited. PetMed Express operates direct-to-consumer pet pharmacy and online pet-product businesses under PetMeds and PetCareRx.
Business Context
On April 3, 2023, the Company acquired PetCareRx for approximately $36.1 million in cash. The acquisition expanded the product catalog by approximately 9,000 items, increased distribution capabilities, and added PetPlus membership revenue. The results of PetCareRx are included from the acquisition date.
Key Financial Metrics
| Metric | Three months ended Sept. 30, 2023 | Three months ended Sept. 30, 2022 | Six months ended Sept. 30, 2023 | Six months ended Sept. 30, 2022 |
|---|---|---|---|---|
| Sales | $71.0 million | $65.4 million | $149.2 million | $135.6 million |
| Sales growth | 8.6% | — | 10.1% | — |
| Gross profit | $20.1 million | $18.5 million | $42.6 million | $38.4 million |
| Gross margin | 28.3% | 28.2% | 28.5% | 28.3% |
| Operating income (loss) | $(0.4) million | $3.0 million | $(2.6) million | $6.5 million |
| Operating margin | (0.6)% | 4.5% | (1.8)% | 4.7% |
| Net income (loss) | $(0.1) million | $2.6 million | $(1.0) million | $5.4 million |
| Net margin | Approximately 0.0% | 3.9% | (0.7)% | 3.9% |
| Adjusted EBITDA | $3.2 million | $7.1 million | $6.5 million | $13.4 million |
- Reorder sales increased 4.5% in the quarter and 6.0% year to date. New-order sales increased 8.9% and 11.8%, respectively.
- Membership fees contributed $2.4 million in the quarter and $4.8 million year to date; there were no comparable membership-fee sales in the prior-year periods.
- AutoShip represented 51.0% of quarterly net sales, compared with 38.9% in the prior-year quarter and 48.7% in the immediately preceding quarter.
- Approximately 76,000 new customers were acquired during the quarter, compared with approximately 61,000 in the prior-year quarter. Year-to-date new customers were approximately 162,000 versus 130,000.
- Advertising expense increased to $5.5 million for the quarter from $3.9 million, and to $12.8 million year to date from $10.2 million. Quarterly customer acquisition cost increased to $73 from $64.
- General and administrative expense increased 23.5% for the quarter and 44.2% year to date, reflecting higher payroll, professional fees, software and systems costs, overhead, and PetCareRx integration expenses.
- Depreciation and amortization increased to $1.7 million for the quarter and $3.4 million year to date, primarily due to acquired intangible assets and property additions.
Cash Flow, Liquidity, Debt, and Capital Allocation
- Cash and cash equivalents were $53.5 million at September 30, 2023, compared with $104.1 million at March 31, 2023.
- Operating cash flow was $(0.2) million for the six months ended September 30, 2023, versus $5.1 million provided in the prior-year period.
- Investing cash flow was $(38.0) million, including $35.9 million for the PetCareRx acquisition and $2.1 million of property and equipment purchases.
- Financing cash flow was $(12.4) million, primarily reflecting dividends paid. The Company declared $0.60 per share for the six-month period.
- Working capital declined to $45.0 million from $95.0 million at March 31, 2023, largely because of the acquisition and related cash use.
- The Company had no debt obligations at September 30, 2023. Operating lease liabilities totaled $1.8 million.
- Approximately $28.7 million remained available under the share repurchase plan.
- On October 30, 2023, the Board suspended the quarterly dividend to direct cash flow toward growth and other higher-return initiatives. Future dividends are discretionary.
Material Changes, Outlook, and Risks
- Sales growth benefited from PetCareRx, membership fees, and new-customer growth, but PetMeds reorder sales growth remained comparatively modest.
- Despite higher sales and gross profit, operating and net profitability declined because expense growth, advertising investment, acquisition-related costs, and higher depreciation and amortization exceeded gross-profit growth.
- The effective tax rate was approximately 118.3% for the quarter and negative 54.6% for the six months, affected by net operating losses, nondeductible items, and state taxes. PetCareRx had approximately $96.0 million of pre-acquisition net operating losses and $1.9 million of disallowed interest expense; preliminary Section 382 analysis limited the combined amount to approximately $33.0 million.
- The Company expects inflation, interest rates, fuel, utility and food costs, supply-chain volatility, recession concerns, competition, and consumer price sensitivity to continue affecting results during fiscal 2024.
- A sales-tax reserve of $6.8 million remained at September 30, 2023. The Company paid $0.7 million related to prior periods and reversed $0.3 million following settlements during the period.
- Goodwill of $22.5 million and acquired intangible assets were recorded in connection with PetCareRx. Valuations used significant Level 3 assumptions, including a 12% discount rate; changes in estimates could affect future impairment or amortization.
- Management stated that disclosure controls were effective as of September 30, 2023, subject to external audit testing. A material weakness disclosed in the prior Form 10-K was reported as remediated after implementation of a segregation-of-duties plan.
- No material changes to previously disclosed risk factors were reported. The filing identifies potential pharmacy-board actions, intellectual-property disputes, ordinary-course litigation, sales-tax exposure, and acquisition-integration risks.
Investor Verification Items
- Verify whether the PetCareRx acquisition produces sustainable revenue, margin, customer-retention, and cost synergies after integration.
- Monitor operating cash flow, cash utilization, and liquidity following the acquisition and dividend suspension.
- Assess whether higher advertising and customer-acquisition costs generate sufficient repeat purchases and lifetime value.
- Track the $6.8 million sales-tax reserve, settlements, and any additional jurisdictional exposure.
- Evaluate the recoverability of $22.5 million of goodwill and acquired intangible assets, including the assumptions used in valuation.
- Confirm the effect of Section 382 limitations on the use of PetCareRx net operating losses and future tax expense.
- Review future filings for control-remediation testing results, dividend policy changes, and developments in the Vetster investment.